And thirdly, higher plasma CRP concentrations were only associated with higher mortality in patients not treated with MCS, but not in those treated with MCS, indicating that MCS use might mitigate the hazardous impact of systemic inflammation in CS. This evidence concerns the gene CRP and Cowden syndrome 1.